Protara Therapeutics, Inc. · NASDAQ:TARA
Protara Therapeutics — American Urological Association Annual Meeting 2025
13 slides from Protara Therapeutics's conference presentation, Apr 28, 2025
Slide 1: Interim Data Presentation from the American Urological Association Annual Meeting April 2025
Interim Data Presentation from the American Urological Association Annual Meeting April 2025
Slide 2: Forward Looking Statements
Forward Looking Statements 2 Statements contained in this presentation regarding matters that are not historical facts are "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 . Protara may, in some cases, use terms such as “predicts,” “believes,” “
Slide 3: Unique Product Characteristics Anticipated to Drive Significant Adoption
Unique Product Characteristics Anticipated to Drive Significant Adoption • Compelling response rates in BCG - UN and BCG - naïve • Encouraging durability observed in patients at 12 months 3 • To date, no Grade 3 or greater treatment - related adverse events • To date, majority of adverse events are
Slide 4: TARA-002 - Lyophilized, Inactivated Group A Streptococcus pyogenes
TARA - 002 Lyophilized, Inactivated Group A Streptococcus pyogenes
Slide 5: Activates Th1 Immune Cascade
Activates Th1 Immune Cascade (1)(2)(3) TARA - 002 is an Investigational, Genetically Distinct Strain of Streptococcus Pyogenes that is Inactivated While Retaining its Immune - Stimulating Properties 5 NK - Cells IL - 1b IL - 6 IL - 12 TNF - α IFN - GM - CSF 1 Fujimoto T., et al. J Immunol. 1997: 5
Slide 6: TARA-002 Monotherapy Demonstrates 100% Complete Response Rate in BCG-Unresponsive Participants
Data cut - off date: 16 April 2025 TARA - 002 Monotherapy Demonstrates 100% Complete Response Rate at Any Time in BCG - Unresponsive Participants 6 n/N (%) ` 5/5 (100.0) High - grade CR at any time 5/5 (100.0) CIS only N/A CIS + Ta/T1 5/5 (100.0) High - grade CR at Month 6 5/5 (100.0) CIS only N/A C
Slide 7: TARA-002 Demonstrates Differentiated Profile to BCG
TARA - 002 BCG Cytokines + -- - IFN - γ +++ + TNF - α + = IL - 12p70 - = IL - 8 + + IL - 6 +++ +++ IL - 1β + = IL - 10 + + IL - 4 = = IL - 13 - - - - IL - 2 TARA - 002 Demonstrates Differentiated Profile to BCG 1 7 = : No change + : 2 - 5 fold upregulation +++ : ≥ 15 - fold upregulation - : 2 - 5 fo
Slide 8: TARA-002 Monotherapy Complete Response in BCG-Naïve Participants
Data cut - off date: 16 April 2025 FOOTNOTE: At the time of data cutoff, 21 participants were evaluated for high - grade CR at Month 3 and later. Sixteen participants were evaluated for high - grade CR at Month 6, eight participants at Month 9, and seven participants at Month 12. Evaluable participa
Slide 9: Favorable and Well-tolerated Safety Profile Across BCG Exposures
Favorable and Well - tolerated Safety Profile Across BCG Exposures 9 Data cut - off date: 16 April 2025 Grade 4/5 Grade 3 Grade 2 Grade 1 Any Grade N=43 0 8 (19) 13 (30) 26 (60) 32 (74) Participants with TEAEs ^, n (%) 0 0 1 (2) 12 (28) 13 (30) Participants with Related TEAEs ^, n (%) 0 0 0 6 (14) 6
Slide 10: Q&A
a 4 ~“bROTARA THERAPEUTICS Q&A
Slide 11: Appendix
oe LEE La APPENDIX
Slide 12: TARA-002 in NMIBC: ADVANCED-2 Clinical Trial Design
Abbreviations: CR = complete response; CIS = carcinoma in situ *Aligned with the FDA’s 2024 BCG Unresponsive NMIBC: Developing Drugs and Biologics for Treatment Guidance for Industry. †Residual CIS and/or recurrence of HGTa Primary endpoint of high - grade complete response (CR) at any time at 6 mon
Slide 13: ADVANCED-2: Demographics and Baseline Characteristics
ADVANCED - 2: Demographics and Baseline Characteristics 13 Data cut - off date: 16 April 2025 ABBREVIATIONS: ECOG= Eastern Cooperative Oncology Group; n = number of participants FOOTNOTE: *The swimmer’s plot excludes 2 participants who withdrew prior to the response assessment; The safety analysis e
Protara Therapeutics — American Urological Association Annual Meeting 2025 on 6ix